SCHEMBL15538191

SCHEMBL15538191

CCC(F)(CC)CN1CCC(COc2ccc(-c3ccc(C(=O)O)c(F)c3)cn2)CC1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RARA P10276 1/20 0.42
RARB P10826 1/20 0.42
GPR119 Q8TDV5 3/20 0.40
CHRM4 P08173 2/20 0.40
ACHE P22303 2/20 0.40
CHRM2 P08172 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
WDR5 P61964 6/20 0.39
SYK P43405 1/20 0.39
SSTR5 P35346 1/20 0.39
KCNH2 Q12809 1/20 0.39
LIPE Q05469 1/20 0.38
ATM Q13315 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16768851 0.93 GPR119 (0.40) RARARARBGPR119CHRM4ACHE
SCHEMBL15538426 0.91 DYRK1A (0.43) RARARARBGPR119CHRM4ACHE
SCHEMBL15539064 0.91 GPR119 (0.39) GPR119CHRM4CHRM2CHRM5CHRM1
SCHEMBL18842719 0.90 GPR119 (0.41) RARARARBGPR119CHRM4ACHE
SCHEMBL16769048 0.89 DGAT1 (0.40) RARARARBGPR119CHRM4ACHE
SCHEMBL20053592 0.89 HCRTR1 (0.40) GPR119WDR5KCNH2LIPEATM
SCHEMBL21535010 0.87 HCRTR1 (0.42) GPR119WDR5LIPEATM
SCHEMBL15539161 0.87 RARA (0.54) RARARARBGPR119CHRM4CHRM2
SCHEMBL16757956 0.87 RARB (0.44) RARARARBGPR119CHRM4CHRM2
SCHEMBL21043258 0.87 MTOR (0.43) GPR119WDR5LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858986-B1 PIPERIDINE DERIVATIVES AS GPR119 AGONISTS CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2019-10-30 EP disclosed
US-9944600-B2 Piperidine derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-04-17 US disclosed
US-9776987-B2 Amide derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-10-03 US disclosed
US-9776987-B2 Amide derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-10-03 US disclosed
US-9776987-B2 Amide derivatives for GPR119 agonist CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-10-03 US disclosed
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-05-11 US disclosed
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-05-11 US disclosed
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-05-11 US disclosed
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-06-18 US disclosed
WO-2015080446-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-06-04 WO disclosed
EP-2858986-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST Chong Kun Dang Pharmaceutical Corp. (KR) 2015-04-15 EP disclosed
WO-2013187646-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166480-A1 PIPERIDINE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GPR84 RARA 825/4885RARB 707/4885GPR119 1/4885
US-20170129875-A1 AMIDE DERIVATIVES FOR GPR119 AGONIST GPR119, FFAR2, GLP1R RARA 735/4885RARB 652/4885GPR119 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.